Addition of Etanercept and Extracorporeal Photopheresis to Standard GVHD Prophylaxis in Patients Undergoing Reduced Intensity Unrelated Donor Hematopoietic Stem Cell Transplant

Trial Profile

Addition of Etanercept and Extracorporeal Photopheresis to Standard GVHD Prophylaxis in Patients Undergoing Reduced Intensity Unrelated Donor Hematopoietic Stem Cell Transplant

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Etanercept (Primary) ; Methoxsalen; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2016 Planned End Date changed from 1 Sep 2015 to 1 May 2016 as per ClinicalTrials.gov record.
    • 19 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top